{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:52:36Z","timestamp":1771901556521,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial\u00ae iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al. Human and material resources utilization was recorded during each iron administration. According to study perspective, direct and indirect costs were considered. Costs for each resource unit were taken from official Italian sources. Probabilistic sensitivity analyses were carried out to test the robustness of the results.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The base case analysis showed an average cost\/cycle per patient of \u20ac 111 for oral iron and \u20ac 1302 for IV iron. Thus, the potential saving was equal to \u20ac 1191 per patient\/cycle. The sensitivity analysis showed that the most sensitive driver is the time loss by patient and caregivers for the therapy and related-care, followed by the minutes of nursing care and the number of kilometres travelled to reach the referral centre.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>This study showed that oral Sucrosomial\u00ae iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-01716-w","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T12:02:43Z","timestamp":1582372963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Oral Sucrosomial\u00ae iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-1104","authenticated-orcid":false,"given":"Eleonora","family":"Riccio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Maria","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Annicchiarico","family":"Petruzzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"1716_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1681\/ASN.2005090997","volume":"17","author":"DL Regidor","year":"2006","unstructured":"Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181\u201391.","journal-title":"J Am Soc Nephrol"},{"key":"1716_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","volume":"34","author":"CY Hsu","year":"1999","unstructured":"Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third National Health and nutrition examination survey. J am Soc Nephrol 2002; 13: 504\u2013510; Levin a, Thompson CR, Ethier J et al. left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125\u201334.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"1716_CR3","first-page":"ii1","volume":"19","author":"F Locatelli","year":"2004","unstructured":"Locatelli F, Aljama P, B\u00e0r\u00e0ny P, et al. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1\u201347.","journal-title":"Nephrol Dial Transplant"},{"key":"1716_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/kisup.2012.34","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:292\u20138.","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"1716_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.ajkd.2015.11.012","volume":"67","author":"LE Ratcliffe","year":"2016","unstructured":"Ratcliffe LE, Thomas W, Glen J, Padhi S, Pordes BA, Wonderling D, Connell R, Stephens S, Mikhail AI, Fogarty DG, Cooper JK, Dring B, Devonald MA, Brown C, Thomas ME. Diagnosis and Management of Iron Deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis. 2016;67(4):548\u201358.","journal-title":"Am J Kidney Dis"},{"key":"1716_CR6","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","volume":"68","author":"IC Macdougall","year":"2005","unstructured":"Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999; 69: S61\u2013S66 15. Van Wyck DB, Roppolo M, Martinez CO et al. a randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846\u201356.","journal-title":"Kidney Int"},{"key":"1716_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000096174","volume":"26","author":"C Charytan","year":"2006","unstructured":"Charytan C, Quinbi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 100: c55\u2013c62. Agarwal R, Rizkala AR, Bastani B et al. a randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26:445\u201354.","journal-title":"Am J Nephrol"},{"key":"1716_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/ndt\/gfu357","volume":"30","author":"A Pisani","year":"2015","unstructured":"Pisani A, Riccio E, Sabbatini M, et al. Effect of oral iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015;30:645\u201352.","journal-title":"Nephrol Dial Transplant"},{"key":"1716_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ejps.2017.10.021","volume":"111","author":"A Fabiano","year":"2017","unstructured":"Fabiano A, Brilli E, Fogli S, Beconcini D, Carpi S, Tarantino G, Zambito Y. Sucrosomial\u00ae iron absorption studied by in vitro and ex-vivo models. Eur J Pharm Sci. 2017;111:425\u201331.","journal-title":"Eur J Pharm Sci"},{"key":"1716_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/nu10030330","volume":"10","author":"L Elli","year":"2018","unstructured":"Elli L, Ferretti F, Branchi F, Tomba C, Lombardo V, Scricciolo A, Doneda L, Roncoroni L. Sucrosomial Iron supplementation in anemic patients with celiac disease not tolerating Oral ferrous sulfate: a prospective study. Nutrients. 2018;10:330.","journal-title":"Nutrients."},{"key":"1716_CR11","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00520-017-3690-z","volume":"25","author":"A Mafodda","year":"2017","unstructured":"Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, Maisano R. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25:2779\u201386.","journal-title":"Support Care Cancer"},{"issue":"8","key":"1716_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17474086.2017.1343140","volume":"10","author":"Sandro Barni","year":"2017","unstructured":"Barni S, Gascon P, Petrelli F, Garcia-Erce JA, Padrazzoli P, Rosti G, Giordano G, Mafodda A, Munoz M. Position paper on management of iron deficiency in adult cancer patients. Expert Rev Hematol. 2017;10(8):685\u201395.","journal-title":"Expert Review of Hematology"},{"key":"1716_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","volume":"107","author":"D Girelli","year":"2018","unstructured":"Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16\u201330.","journal-title":"Int J Hematol"},{"key":"1716_CR14","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care Programmes. J Epidemiol Community Health. 2006;60:822\u201323."},{"key":"1716_CR15","unstructured":"Autorit\u00e0 Nazionale Anticorruzone. Delibera numero 212 del 02\/03\/2016. Prezzi di riferimento dei dispositivi medici: siringhe, ovatta di cotone e cerotti \u2013 Fascicolo REG\/UCS\/03\/2016."},{"key":"1716_CR16","unstructured":"Agenzia Italiana del Farmaco. Riclassificazione del medicinale per uso umano \u00abFerlixit\u00bb (gluconato ferrico sodico), ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 830\/2014). (14A06430) (GU Serie Generale n.188 del 14-08-2014)."},{"key":"1716_CR17","unstructured":"Tabelle Aci 2018: tariffe rimborso chilometrico. Gazzetta Ufficiale n. 302, 29 dicembre 2017."},{"key":"1716_CR18","unstructured":"https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Wages_and_labour_costs\/it."},{"key":"1716_CR19","first-page":"243","volume":"33","author":"M Gianino","year":"2009","unstructured":"Gianino M, Petrinco M, Ferrando A, Galzerano M, Gregori D, Pagano E. Methodological aspects in valuing loss of production and informal care in cost-of-illness studies. Epidemiol Prev. 2009;33:243\u20137.","journal-title":"Epidemiol Prev"},{"key":"1716_CR20","unstructured":"Agenzia Italiana del Farmaco (AIFA). Nota Informativa Importante su medicinali contenenti ferro (25\/10\/2013)."},{"key":"1716_CR21","unstructured":"Ministero della Salute Decreto 18 ottobre 2012. Allegato 1. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale."},{"issue":"2","key":"1716_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hec.4730030206","volume":"3","author":"A Briggs","year":"1994","unstructured":"Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3(2):95\u2013104.","journal-title":"Health Econ"},{"issue":"4","key":"1716_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/j.seminhematol.2018.04.006","volume":"55","author":"AA Khalafallah","year":"2018","unstructured":"Khalafallah AA, Hyppa A, Chuang A, Hanna F, Wilson E, Kwok C, Yan C, Gray Z, Mathew R, Falloon P, Dennis A, Pavlov T, Allen JC. A prospective randomised controlled trial of a single intravenous infusion of ferric Carboxymaltose vs single intravenous Iron Polymaltose or daily Oral ferrous Sulphate in the treatment of Iron deficiency Anaemia in pregnancy. Semin Hematol. 2018;55(4):223\u201334.","journal-title":"Semin Hematol"},{"issue":"5","key":"1716_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40258-019-00481-8","volume":"17","author":"Simon Walker","year":"2019","unstructured":"Walker S, Griffin S, Asaria M, Tsuchiya A, Sculpher M. Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision markets. Appl Health Econ Health policy. 2019;17(5):577\u201390.","journal-title":"Applied Health Economics and Health Policy"},{"issue":"4","key":"1716_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/ph11040097","volume":"11","author":"Susana G\u00f3mez-Ram\u00edrez","year":"2018","unstructured":"G\u00f3mez-Ramirez S, Brilli E, Tarantino G, Mu\u00f1oz M. Sucrosmial \u00ae Iron: A New Genereation Iron for Improving Oral Supplementation. Pharmaceuticals (Basel). 2018;11(4):97.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"1716_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40261-018-0666-9","volume":"38","author":"J Darb\u00e0","year":"2018","unstructured":"Darb\u00e0 J, Ascanio M. Budget impact analysis of Oral Fisiogen Ferro forte(\u00ae) versus intravenous Iron for the Management of Iron Deficiency in chronic kidney disease in Spain. Clin Drug Investig. 2018;38(9):801\u201311.","journal-title":"Clin Drug Investig"},{"issue":"Suppl. S1","key":"1716_CR27","first-page":"15","volume":"9","author":"G Giordano","year":"2016","unstructured":"Giordano G. Oral high-dose Sucrosomial\u00ae Iron vs. intravenous iron in sideropenic anemia intolerant\/refractory to iron sulfate. Multicentric randomized study. Expert Rev Hematol. 2016;9(Suppl. S1):15\u20137.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"1716_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00264-018-4149-7","volume":"43","author":"Marco Scardino","year":"2018","unstructured":"Scardino M, Di Matteo B, Martorelli F, Tanzi D, Kon E, D'Amato T. Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial\u00ae iron supplementation: a quality improvement assessement study. Int Orthop. 2019;43(1):39\u201346.","journal-title":"International Orthopaedics"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-01716-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T02:32:41Z","timestamp":1613874761000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01716-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01716-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,22]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Medical Ethics Committee \u201cCarlo Romano\u201d, of the University Federico II of Naples, and was in adherence with the Declaration of Helsinki. Informed written consent was obtained from each patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AP received reimbursement for attending symposiums and fees for speaking by Pharmanutra S.P.A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}